Divi's Laboratories Ltd.
₹9,715.00+₹60.00 (+0.6%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹1,70,791 Cr
- P/E
- 67.9x
- EV / EBITDA
- 67.2x
- Revenue
- ₹9,198 Cr
- Net margin
- 20.6%
- ROCE
- 16.2%
Price chart
Technical chartScreen technicals →+46.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +4.7%
- 3M
- +23.9%
- 6M
- +49.3%
- 1Y
- +46.0%
- 5Y
- +86.6%
52-week range
Day change +₹60.00 (+0.6%) from ₹9,655 to ₹9,715 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in DIVISLAB, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 50.0%
Concerns0
Rule-based from financial data. Not advice.
About the company
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally.
Read moreShow less
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 26.5 Cr shares
- ISIN
- INE361B01024
- BSE code
- 532488
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹1,70,791 Cr
- P/E
- 67.9x
- P/B
- 11.1x
- EV / EBITDA
- 67.2x
- EV / Sales
- 22.0x
- P/S
- 22.3x
- Earnings yield
- 1.5%
- 52-week high
- ₹9,715.00
- 52-week low
- ₹5,810.25
Profitability
- Operating margin
- 28.4%
- Net margin
- 20.6%
- EBITDA margin
- 32.8%
- ROE
- 11.7%
- ROCE
- 16.2%
- ROA
- 10.3%
- Dividend payout
- 50.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 15.6%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹9,198 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 20.0%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.6%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,512 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -6.9%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 40.2%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.8%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,266 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -48.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹50.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.0%
Solvency and efficiency
- Current ratio
- 5.24
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- Interest coverage
- 544.75
- Financial leverage
- 1.14
- CFO / Net profit
- 0.80
- Cash / Market cap
- 5.7%
- Cash per share
- ₹367.72
- Asset turnover
- 0.50
- Fixed asset turnover
- 1.62
- Capital intensity
- 0.62
- Debtor days
- 108 days
- Inventory turnover
- 1.05
- Cash conversion cycle
- 361 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹24 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹6,214 Cr |
| Sales | Operating profit | ₹2,984 Cr |
| Operating profit | Interest | ₹2 Cr |
| Operating profit | Depreciation | ₹401 Cr |
| Operating profit | Profit before tax | ₹2,581 Cr |
| Other income | Profit before tax | ₹348 Cr |
| Profit before tax | Tax and other | ₹720 Cr |
| Profit before tax | Net profit | ₹2,209 Cr |
Revenue and net profit
Revenue grew 20.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹6,799 Cr | ₹1,955 Cr |
| FY2022 | ₹8,880 Cr | ₹2,949 Cr |
| FY2023 | ₹7,625 Cr | ₹1,808 Cr |
| FY2024 | ₹7,665 Cr | ₹1,576 Cr |
| FY2025 | ₹9,198 Cr | ₹2,209 Cr |
Cash flows
FY2025: ₹1,650 Cr from operations, ₹847 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹1,947 Cr | ₹2,022 Cr |
| FY2022 | ₹1,910 Cr | -₹285 Cr |
| FY2023 | ₹2,447 Cr | -₹260 Cr |
| FY2024 | ₹1,266 Cr | ₹998 Cr |
| FY2025 | ₹1,650 Cr | ₹847 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹9,198 Cr+20.0%1Y
- Net profit
- ₹2,209 Cr+40.2%1Y
- Cash from operations
- ₹1,650 Cr
- Free cash flow
- ₹847 Cr-15.1%1Y
- Revenue CAGR, 5Y
- 7.6%
- EBITDA CAGR, 5Y
- 4.6%
- Net profit CAGR, 5Y
- 2.8%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹9,198 Cr | ₹2,984 Cr | — | ₹2,209 Cr | ₹1,650 Cr | ₹847 Cr | 14.8% | +20.0% | +40.2% |
Monthly returns
Month-by-month returns of DIVISLAB across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹16,824 Cr |
| Equity capital | ₹53 Cr |
| Reserves | ₹14,842 Cr |
| Borrowings | ₹2 Cr |
| Other liabilities | ₹1,927 Cr |
| Assets | ₹16,824 Cr |
| Fixed assets | ₹5,440 Cr |
| Capital work in progress | ₹1,022 Cr |
| Investments | ₹72 Cr |
| Other assets | ₹10,290 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
DIVISLAB trades at 67.9x earnings against a peer median of 52.6x (a 29% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Divi's Laboratories Ltd.DIVISLABthis companyP/E ↑ premium | ₹1.7 L Cr | 67.9x | 11.1x | 11.7% | 67.2x |
| Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.3 L Cr | 62.5x | 15.8x | 19.9% | 45.6x |
| Cipla Ltd.CIPLA | ₹1.2 L Cr | 22.5x | 3.5x | 14.6% | 19.3x |
| Apollo Hospitals Enterprises Ltd.APOLLOHOSP | ₹1.1 L Cr | 75.0x | 11.3x | 13.1% | 54.4x |
| Max Healthcare Institute LimitedMAXHEALTH | ₹1.0 L Cr | 144.0x | 11.8x | 8.9% | 96.8x |
| Lupin LtdLUPIN | ₹99,475 Cr | 18.6x | 3.7x | 11.3% | 27.4x |
| Dr. Reddy's Laboratories Ltd.DRREDDY | ₹99,417 Cr | 18.4x | 3.2x | 17.9% | 14.3x |
| Mankind Pharma LimitedMANKIND | ₹91,284 Cr | 54.8x | 5.9x | 19.3% | 34.3x |
| Zydus Lifesciences LimitedZYDUSLIFE | ₹90,637 Cr | 18.8x | 4.2x | 21.9% | 18.4x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
DIVISLAB since 1 January, against earlier years.
Historical volatility
DIVISLAB's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 42.0% |
| FY2022 | 44.0% |
| FY2023 | 31.0% |
| FY2024 | 28.0% |
| FY2025 | 32.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹9,198 Cr |
| Costs | |
| Interest | ₹2 Cr |
| Expenses | ₹6,214 Cr |
| Operating profitOperating Profit | ₹2,984 Cr |
| Other income and charges | |
| Profit before tax | ₹2,929 Cr |
| Tax | |
| Net profitNet Profit | ₹2,209 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹16,824 Cr |
| Equity capitalEquity Capital | ₹53 Cr |
| Reserves | ₹14,842 Cr |
| Borrowings | ₹2 Cr |
| Other liabilitiesOther Liabilities | ₹1,927 Cr |
| AssetsTotal Assets | ₹16,824 Cr |
| Fixed assetsFixed Assets | ₹5,440 Cr |
| Capital work in progressCWIP | ₹1,022 Cr |
| Investments | ₹72 Cr |
| Other assetsOther Assets | ₹10,290 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹1,650 Cr |
| Investing cash flowCash from Investing Activity | -₹803 Cr |
| Financing cash flowCash from Financing Activity | -₹797 Cr |
| Change in cashNet Cash Flow | ₹50 Cr |
Learn while you research
Academy chapters picked for Divi's Laboratories Ltd. and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 67.9, learn when high multiples are justified.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read